Navigation Links
Phase 3 trials of two multi-kinase inhibitors against cancer

Sorafenib and stutent multi-kinase inhibitors against cancer is undergoing phase 3 trials// and these two drugs gained more appreciation in this years ASCO (American Society of Clinical Oncology) conference. This drug is gaining interest due to its multiple mechanism of action – known as Multi-kinase inhibitors. These drugs are in trial against different types of cancer and are found to be very effective. This two multi targeted oncology drug candidate is a small molecule named Sorafenib (Bay43-9006) and stutent (SU11248).

Sorafenib is produced by Onyx pharmaceuticals of California collaborating with Bayer pharmaceuticals of Connecticut and Stutent by Pfizer of New York city. Both these drugs are undergoing phase 3 trials.

Results of the study show that Sorafenib in advanced kidney cancer patients taking the drug lived twice as long as that placebo. Gleevec (imatinib) resistant gastrointestinal stromal tumors (GIST) were much less likely to progress in patients taking stutent versus those on placebo.

Both these drug act against tumor and its ability to recruit new blood vessels essential for growth and dissemination via multiple mechanisms. Sorafenib works by inhibiting the RAF/MEK/ERK pathway and, in parallel, impedes angiogenesis by inhibiting vascular endothelial growth factor-2 (VEGF-2) and platelet derived growth factor beta (PDGF- a). Stutent also has dual actions, killing VEGF and PDGF- á and a as well as FLT-3 and C-KIT.

Pfizer is developing more multi-targeted cancer drugs, such as small AG-013736 which has encouraging results in its phase 2 trials in kidney cancer.

Multi-targeted drug has also downsides of having side effects and allow less flexibility. But, so far there was no side effects reported in Sorafenib or stutent.


Page: 1

Related medicine news :

1. SARS-Free Taiwan to Mark End Phase of Global Fight
2. Spray on contraceptive clears Phase I trial
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. Phase II trails of new HIV vaccine to be held in South Africa
5. FDA approves Phase 0 trial which tests experimental drugs on humans
6. Jalgaon: Third Phase Of Culling Operations Begin
7. Phase 1 Drug Trials on Humans to Be Made Public
8. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
9. Cadila to Commence Phase I Clinical Trials On ZYH2
10. iGATE Completes Phase I Testing Of Meningitis Vaccine
11. ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented
Post Your Comments:

(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology: